Monitor Q4 2026 topline data for DA-1726 Part 3 readout. Positive weight loss and tolerability data could be a catalyst for this ~$8M market cap company, but today's update is incremental and not actionable on its own.
Price Chart
Executive Summary
MetaVia announced that all enrolled active patients in Part 3 of its Phase 1 trial for DA-1726 (obesity) have successfully completed dose titration and reached highest target doses (48 mg and 64 mg). Topline data remains on track for Q4 2026.
Key Facts
- All active patients in Part 3A and Part 3B reached their highest target doses of 48 mg and 64 mg, respectively.
- Phase 1 Part 3 trial has ~40 subjects, randomized 4:1 active to placebo.
- Topline data from Part 3 is expected in Q4 2026.
- DA-1726 is a GLP-1/glucagon dual agonist for obesity and MASH.
- Prior Phase 1 MAD data showed 9.1% mean weight loss at 48 mg over 8 weeks.
Financial Impact
No financial data disclosed; clinical milestone with no revenue implications at this stage.
Risk Factors
- Clinical trial failure or disappointing efficacy/safety in Q4 readout
- Cash burn risk for clinical-stage biotech without revenue
- Competition from established GLP-1 drugs (semaglutide, tirzepatide)
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001104659-26-082116 |
| Document: tm2620006d1_ex99-1.htm | 0001104659-26-082116 |
| Document: 0001104659-26-082116-index-headers.html | 0001104659-26-082116 |
| Document: 0001104659-26-082116-index.html | 0001104659-26-082116 |
| Document: 0001104659-26-082116.txt | 0001104659-26-082116 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 13, 2026 13d ago | 3 | $1.36 | awaiting T+20 | — | $1.22 (−10.66%) |
Oct 13, 2026 13d ago | 8-K | $1.43 | awaiting T+20 | — | $1.22 (−15.03%) |
Sep 9, 2026 6w ago | 8-K | $1.74 $1.46 | ▼ −16.09% | ▼ −18.04% | $1.22 (−30.17%) |
Jul 9, 2026 15w ago | 8-K | $1.73 $1.45 | ▼ −16.18% | ▼ −18.43% | $1.22 (−29.77%) |
Jul 2, 2026 16w ago | 424B5 | $1.48 $1.44 | ▲ +2.70% | ▲ +2.29% | $1.22 (+17.91%) |
Jun 8, 2026 20w ago | 8-K | $1.89 $1.58 | ▼ −16.40% | ▼ −17.85% | $1.22 (−35.71%) |
Jun 8, 2026 20w ago | 8-K | $2.22 $1.51 | ▼ −31.98% | ▼ −33.61% | $1.22 (−45.27%) |
May 27, 2026 21w ago | 8-K | $3.34 $1.53 | ▼ −54.19% | ▼ −52.29% | $1.22 (−63.62%) |
May 18, 2026 23w ago | 8-K | $1.11 $1.65 | ▲ +48.65% | ▲ +47.07% | $1.22 (+9.46%) |
May 14, 2026 23w ago | 8-K | $1.11 $1.71 | ▲ +54.05% | ▲ +51.94% | $1.22 (+9.46%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers